#aluminiumtoxicity

[debaprasad]

Emotion of Motion: Piramal Pharma’s Naturolax and the Politics of the Gut

Posted on 16th December, 2025 (GMT 06:52 hrs) Updated on 17th December, 2025 (GMT 04:50 hrs) ABSTRACT Inspired by Chekhov’s “On the Harmful Effects of Tobacco”, this self-reflexive, darkly satirical essay stages constipation as a material, political, and ecological symptom of contemporary Indian capitalism, tracing an embodied genealogy from the Green Revolution’s chemical agriculture to…

View On WordPress

[debaprasad]

Ajay Piramal's Pharma Empire: Saridon, Polycrol and Tetmosol by DebaprasadBandyopadhyay Via Flickr: These petition-letters address the intersecting ethical, medical, financial, and regulatory failures embodied in the Piramal Pharma’s practices, weaving together the cases of Tetmosol, Polycrol, and Saridon as both concrete products and metaphors of systemic exploitation. It highlights how Tetmosol (Monosulfiram)—an obsolete, unapproved dermatological product absent from global pharmacopoeia yet still marketed in India and exported to vulnerable populations in the Global South—mirrors the structural injustice of the DHFL resolution that allegedly stripped ordinary depositors of their savings: a superficial balm masking deeper wounds, profit extracted from public vulnerability, and corporate narratives of “conscious capitalism” greenwashing exploitation. Polycrol, marketed as an over-the-counter antacid, offers only temporary relief while containing aluminium compounds associated with neurotoxic, skeletal, renal, and haematological risks, with no robust long-term efficacy evidence, thereby exemplifying the quick-fix, extractive logic of crony capitalism that normalizes self-medication, manipulates regulatory loopholes, and thrives on celebrity endorsements amidst widespread pesticide exposure. Saridon, despite its global ban, continues to be advertised in India as a “triple action” cure, its composition of Paracetamol, Propyphenazone, and Caffeine symbolically exposing how legality cloaks long-term harm, judicial indulgence entrenches asymmetry, and profit-driven stimulation deepens precarity—echoing the DHFL crisis where commerce, law, and politics collude to perpetuate inequity. By situating these pharmaceutical products within a broader “pharma-political” nexus of regulatory laxity, corporate profiteering, and judicial complicity, the letter invokes the concepts of iatrogenic harm and “medical nemesis” to argue that both medical and financial mis-selling constitute analogous public harms requiring urgent redress. It therefore calls for regulatory review by CDSCO, WHO, and international agencies; withdrawal of unsafe and outdated drugs from the Indian market; alignment of pharmaceutical and financial practices with global safety norms; establishment of an independent redressal mechanism for DHFL victims; and the recognition that systemic reform, not symptomatic relief, is essential to safeguard public health, justice, and societal well-being.

[debaprasad]

Ajay Piramal's Pharma Empire: Saridon, Polycrol and Tetmosol by DebaprasadBandyopadhyay Via Flickr: These petition-letters address the intersecting ethical, medical, financial, and regulatory failures embodied in the Piramal Pharma’s practices, weaving together the cases of Tetmosol, Polycrol, and Saridon as both concrete products and metaphors of systemic exploitation. It highlights how Tetmosol (Monosulfiram)—an obsolete, unapproved dermatological product absent from global pharmacopoeia yet still marketed in India and exported to vulnerable populations in the Global South—mirrors the structural injustice of the DHFL resolution that allegedly stripped ordinary depositors of their savings: a superficial balm masking deeper wounds, profit extracted from public vulnerability, and corporate narratives of “conscious capitalism” greenwashing exploitation. Polycrol, marketed as an over-the-counter antacid, offers only temporary relief while containing aluminium compounds associated with neurotoxic, skeletal, renal, and haematological risks, with no robust long-term efficacy evidence, thereby exemplifying the quick-fix, extractive logic of crony capitalism that normalizes self-medication, manipulates regulatory loopholes, and thrives on celebrity endorsements amidst widespread pesticide exposure. Saridon, despite its global ban, continues to be advertised in India as a “triple action” cure, its composition of Paracetamol, Propyphenazone, and Caffeine symbolically exposing how legality cloaks long-term harm, judicial indulgence entrenches asymmetry, and profit-driven stimulation deepens precarity—echoing the DHFL crisis where commerce, law, and politics collude to perpetuate inequity. By situating these pharmaceutical products within a broader “pharma-political” nexus of regulatory laxity, corporate profiteering, and judicial complicity, the letter invokes the concepts of iatrogenic harm and “medical nemesis” to argue that both medical and financial mis-selling constitute analogous public harms requiring urgent redress. It therefore calls for regulatory review by CDSCO, WHO, and international agencies; withdrawal of unsafe and outdated drugs from the Indian market; alignment of pharmaceutical and financial practices with global safety norms; establishment of an independent redressal mechanism for DHFL victims; and the recognition that systemic reform, not symptomatic relief, is essential to safeguard public health, justice, and societal well-being.

[debaprasad]

Ajay Piramal's Pharma Empire: Saridon, Polycrol and Tetmosol by DebaprasadBandyopadhyay Via Flickr: These petition-letters address the intersecting ethical, medical, financial, and regulatory failures embodied in the Piramal Pharma’s practices, weaving together the cases of Tetmosol, Polycrol, and Saridon as both concrete products and metaphors of systemic exploitation. It highlights how Tetmosol (Monosulfiram)—an obsolete, unapproved dermatological product absent from global pharmacopoeia yet still marketed in India and exported to vulnerable populations in the Global South—mirrors the structural injustice of the DHFL resolution that allegedly stripped ordinary depositors of their savings: a superficial balm masking deeper wounds, profit extracted from public vulnerability, and corporate narratives of “conscious capitalism” greenwashing exploitation. Polycrol, marketed as an over-the-counter antacid, offers only temporary relief while containing aluminium compounds associated with neurotoxic, skeletal, renal, and haematological risks, with no robust long-term efficacy evidence, thereby exemplifying the quick-fix, extractive logic of crony capitalism that normalizes self-medication, manipulates regulatory loopholes, and thrives on celebrity endorsements amidst widespread pesticide exposure. Saridon, despite its global ban, continues to be advertised in India as a “triple action” cure, its composition of Paracetamol, Propyphenazone, and Caffeine symbolically exposing how legality cloaks long-term harm, judicial indulgence entrenches asymmetry, and profit-driven stimulation deepens precarity—echoing the DHFL crisis where commerce, law, and politics collude to perpetuate inequity. By situating these pharmaceutical products within a broader “pharma-political” nexus of regulatory laxity, corporate profiteering, and judicial complicity, the letter invokes the concepts of iatrogenic harm and “medical nemesis” to argue that both medical and financial mis-selling constitute analogous public harms requiring urgent redress. It therefore calls for regulatory review by CDSCO, WHO, and international agencies; withdrawal of unsafe and outdated drugs from the Indian market; alignment of pharmaceutical and financial practices with global safety norms; establishment of an independent redressal mechanism for DHFL victims; and the recognition that systemic reform, not symptomatic relief, is essential to safeguard public health, justice, and societal well-being.

[debaprasad]

Ajay Piramal's Pharma Empire: Saridon, Polycrol and Tetmosol by DebaprasadBandyopadhyay Via Flickr: These petition-letters address the intersecting ethical, medical, financial, and regulatory failures embodied in the Piramal Pharma’s practices, weaving together the cases of Tetmosol, Polycrol, and Saridon as both concrete products and metaphors of systemic exploitation. It highlights how Tetmosol (Monosulfiram)—an obsolete, unapproved dermatological product absent from global pharmacopoeia yet still marketed in India and exported to vulnerable populations in the Global South—mirrors the structural injustice of the DHFL resolution that allegedly stripped ordinary depositors of their savings: a superficial balm masking deeper wounds, profit extracted from public vulnerability, and corporate narratives of “conscious capitalism” greenwashing exploitation. Polycrol, marketed as an over-the-counter antacid, offers only temporary relief while containing aluminium compounds associated with neurotoxic, skeletal, renal, and haematological risks, with no robust long-term efficacy evidence, thereby exemplifying the quick-fix, extractive logic of crony capitalism that normalizes self-medication, manipulates regulatory loopholes, and thrives on celebrity endorsements amidst widespread pesticide exposure. Saridon, despite its global ban, continues to be advertised in India as a “triple action” cure, its composition of Paracetamol, Propyphenazone, and Caffeine symbolically exposing how legality cloaks long-term harm, judicial indulgence entrenches asymmetry, and profit-driven stimulation deepens precarity—echoing the DHFL crisis where commerce, law, and politics collude to perpetuate inequity. By situating these pharmaceutical products within a broader “pharma-political” nexus of regulatory laxity, corporate profiteering, and judicial complicity, the letter invokes the concepts of iatrogenic harm and “medical nemesis” to argue that both medical and financial mis-selling constitute analogous public harms requiring urgent redress. It therefore calls for regulatory review by CDSCO, WHO, and international agencies; withdrawal of unsafe and outdated drugs from the Indian market; alignment of pharmaceutical and financial practices with global safety norms; establishment of an independent redressal mechanism for DHFL victims; and the recognition that systemic reform, not symptomatic relief, is essential to safeguard public health, justice, and societal well-being.

[debaprasad]

Where Have All The Flowers Gone? Disclosing Piramal Pharma’s “Little’s” by DebaprasadBandyopadhyay Via Flickr: onceinabluemoon2021.in/2025/10/15/where-have-all-the-flow... This investigative article, dedicated to the twenty-two children who perished from contaminated cough syrup in India—a stark emblem of systemic regulatory failure, profit-driven negligence, and ethical erosion in the pharmaceutical sector—unveils the moral contradictions embedded in Piramal Pharma’s “Little’s” baby-care line, encompassing wipes, oils, powders, shampoos, diapers, toys, and the whimsical “Jungle Magic” extensions like perfumes, sanitizers, and repellents. Through a meticulous dissection of product variants, their petrochemical-derived ingredients (such as talc, polypropylene, parabens, phenoxyethanol, and superabsorbent polymers), and associated health risks—including asbestos contamination, endocrine disruption, microplastic ingestion, respiratory hazards, and unverified pediatric safety—it exposes how corporate rhetoric of “gentle care” and “purity” masks a toxic alchemy of commodified infancy, where parental anxiety is monetized amid opaque supply chains reliant on Chinese imports (15% of raw materials), environmental externalities like Digwal’s pollution, and regulatory gray zones that classify these as non-pharmacological FMCG rather than scrutinized drugs. Interweaving poetic laments, folk songs, philosophical dialogues, and political-ecological critiques, the piece frames infancy as a battleground of postcolonial capitalism, where the cradle mirrors the coffin through iatrogenic harm, false patriotism (boycotting Chinese goods in rhetoric while importing them in practice), and the Anthropocene’s uninhabitable legacy of climate toxicity and microplastics; appendices provide granular data on toy industry economics, material toxicities, and sourcing hypotheses, culminating in demands for transparency, independent audits, pharmacovigilance for consumer goods, and a reclamation of nurture from market fetishism to honor the lost children not as accidents but as indictments urging societal reform and remembrance. Tragedy and Dedication: Investigates deaths of 22 children from contaminated cough syrup in India, exposing systemic regulatory failure and negligence in pharmaceuticals. Piramal Pharma’s “Little’s” Line: Critiques baby-care products (wipes, oils, shampoos, diapers, toys, “Jungle Magic” extensions) for masking toxic ingredients with “gentle care” rhetoric. Health Risks: Highlights dangers from petrochemical-derived ingredients (talc, polypropylene, parabens, phenoxyethanol, superabsorbent polymers), including asbestos, endocrine disruption, microplastics, respiratory issues, and unverified pediatric safety. Opaque Supply Chains: Notes reliance on Chinese imports (15% of raw materials), environmental pollution (e.g., Digwal), and lax regulation of non-pharmacological FMCG products. Moral and Cultural Critique: Frames infancy as a battleground of postcolonial capitalism, with iatrogenic harm, false patriotism, and Anthropocene-driven toxicity (climate, microplastics). Data and Demands: Includes appendices on toy industry economics, material toxicities, and sourcing; calls for transparency, audits, pharmacovigilance, and societal reform to honor the lost children.

[debaprasad]

Where Have All The Flowers Gone? Disclosing Piramal Pharma’s “Little’s” by DebaprasadBandyopadhyay Via Flickr: onceinabluemoon2021.in/2025/10/15/where-have-all-the-flow... This investigative article, dedicated to the twenty-two children who perished from contaminated cough syrup in India—a stark emblem of systemic regulatory failure, profit-driven negligence, and ethical erosion in the pharmaceutical sector—unveils the moral contradictions embedded in Piramal Pharma’s “Little’s” baby-care line, encompassing wipes, oils, powders, shampoos, diapers, toys, and the whimsical “Jungle Magic” extensions like perfumes, sanitizers, and repellents. Through a meticulous dissection of product variants, their petrochemical-derived ingredients (such as talc, polypropylene, parabens, phenoxyethanol, and superabsorbent polymers), and associated health risks—including asbestos contamination, endocrine disruption, microplastic ingestion, respiratory hazards, and unverified pediatric safety—it exposes how corporate rhetoric of “gentle care” and “purity” masks a toxic alchemy of commodified infancy, where parental anxiety is monetized amid opaque supply chains reliant on Chinese imports (15% of raw materials), environmental externalities like Digwal’s pollution, and regulatory gray zones that classify these as non-pharmacological FMCG rather than scrutinized drugs. Interweaving poetic laments, folk songs, philosophical dialogues, and political-ecological critiques, the piece frames infancy as a battleground of postcolonial capitalism, where the cradle mirrors the coffin through iatrogenic harm, false patriotism (boycotting Chinese goods in rhetoric while importing them in practice), and the Anthropocene’s uninhabitable legacy of climate toxicity and microplastics; appendices provide granular data on toy industry economics, material toxicities, and sourcing hypotheses, culminating in demands for transparency, independent audits, pharmacovigilance for consumer goods, and a reclamation of nurture from market fetishism to honor the lost children not as accidents but as indictments urging societal reform and remembrance. Tragedy and Dedication: Investigates deaths of 22 children from contaminated cough syrup in India, exposing systemic regulatory failure and negligence in pharmaceuticals. Piramal Pharma’s “Little’s” Line: Critiques baby-care products (wipes, oils, shampoos, diapers, toys, “Jungle Magic” extensions) for masking toxic ingredients with “gentle care” rhetoric. Health Risks: Highlights dangers from petrochemical-derived ingredients (talc, polypropylene, parabens, phenoxyethanol, superabsorbent polymers), including asbestos, endocrine disruption, microplastics, respiratory issues, and unverified pediatric safety. Opaque Supply Chains: Notes reliance on Chinese imports (15% of raw materials), environmental pollution (e.g., Digwal), and lax regulation of non-pharmacological FMCG products. Moral and Cultural Critique: Frames infancy as a battleground of postcolonial capitalism, with iatrogenic harm, false patriotism, and Anthropocene-driven toxicity (climate, microplastics). Data and Demands: Includes appendices on toy industry economics, material toxicities, and sourcing; calls for transparency, audits, pharmacovigilance, and societal reform to honor the lost children.

[debaprasad]

Between Cosmetic Grooming, Pharmacology and DHFL Haircut: Ambiguities in the Case of Bohem by Piramal Pharma Limited

Posted on 25th October, 2025 (GMT 06:16 hrs) ABSTRACT This paper investigates the regulatory and ethical positioning of Bohem, a men’s grooming product line launched by Piramal Pharma Limited (PPL), within the Indian cosmetic–drug regulatory framework. Drawing upon publicly available documents from the Central Drugs Standard Control Organisation (CDSCO), Piramal Pharma’s corporate…

View On WordPress